FILING ANALYSIS · MONDAY, NOVEMBER 16

Eloxx Pharmaceuticals, Inc. ELOX — 8-K: Results of Operations and Financial Condition

neutral

Eloxx Pharmaceuticals reported Q3 financial results and a business update, including dosing the first two patients in the global Phase 2b EXACT study and finalizing the protocol for the Phase 2 EXPRESS study, with cash and cash equivalents of $56.3 million as of September 30, 2026. No significant quantified surprises were disclosed in the filing.

The filing

8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+